Cladribine Injection Application Scope

Cladribine injection is primarily indicated for the treatment of active hairy cell leukemia, characterized by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms.

cladribine injection

Cladribine Injection Characteristics

Ingredients: The active ingredient is cladribine. Inactive ingredients include dibasic sodium phosphate, phosphoric acid, sodium chloride, and water for injection.
Properties: Cladribine is a purine nucleoside analog that interferes with DNA synthesis, leading to the death of certain white blood cells, particularly lymphocytes and monocytes.
Specification: 10 mg (1 mg/mL) .
Packaging Specification: Available in packages of 25 individually boxed vials.
Storage: Keep sealed.
Expiry Date: Refer to the packaging for the specific expiry date.
Executive Standard: YBH33322005
Approval Number: National Drug Code H20052240
Date of Revision: Refer to the product insert for the most recent revision date.
Manufacturer: Hazen Pfizer Pharmaceuticals Ltd.

Guidelines for the Use of Cladribine Injection

Dosage and Administration: The recommended dosage for hairy cell leukemia is 0.09 mg/kg/day administered by continuous intravenous infusion for 7 consecutive days. Cladribine injection should be administered under the supervision of a qualified physician experienced in the use of antineoplastic therapy.
Adverse Reactions: Common adverse reactions include bone marrow suppression leading to anemia, neutropenia, and thrombocytopenia; fever; infection; and fatigue. Serious neurological toxicity, including irreversible paraparesis and quadriparesis, has been reported at high doses. Acute nephrotoxicity has also been observed with high doses.

Medication Limitations

Contraindications: Cladribine injection is contraindicated in patients with hypersensitivity to cladribine or any of its components. It is also contraindicated during pregnancy and lactation.
Precautions: Suppression of bone marrow function should be anticipated, and patients should be monitored for hematologic and non-hematologic toxicity. Significant and prolonged lymphopenia has been noted. Caution is advised when administering cladribine to patients with known or suspected renal or hepatic insufficiency.

Cladribine Injection Interactions

Drug Interactions: The tumor-suppressive activity of Cladribine is related to deoxycytidine kinase and deoxyribonucleotide kinase activities. It enters the cell mainly by passive transport, and is phosphorylated by deoxycytidine kinase in the cell, converted to cladribine triphosphate, doped into the DNA molecule, impeding the repair of DNA after breakage, causing the depletion of NAD and ATP, disrupting cellular metabolism, and affecting DNA synthesis of the cell. Therefore, this product has the effect of inhibiting DNA synthesis and repair on both lymphocytes and monocytes in differentiation or quiescent phase.
Please note that while cladribine has demonstrated efficacy in treating hairy cell leukemia, its use should be based on clinical evidence and under the guidance of a qualified healthcare professional.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.